Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Kennedy researchers, in collaboration with colleagues at the Botnar Research Centre, Oxford, and the Universities of Birmingham and Leeds, have been awarded strategic funding from the Medical Research Council (MRC) to map in detail the different types of cells that make up human joints.

Diseases of the joint are a leading cause of disability in the UK. Many joint diseases cannot be cured with existing therapies and there are very few – if any – treatments available to stimulate repair of damaged joint tissues. 

The new research led by the Kennedy Institute will characterise all cell types in healthy synovial joints in order to better understand what goes wrong in disease. These studies will extend current knowledge of disease genetics and facilitate the identification of new therapies by generating an understanding of the cellular basis of joint disease.

The funding for the project was secured by Professor Christopher Buckley, Director of Clinical Research at the Kennedy Institute, and is co-led by Dr Stephen Sansom and Professor Mark Coles. 

“Establishing the cellular basis for diseases is a major challenge for the 21st century so that pathogenic pathways and processes can be ascribed to the right cell in the right organ at the right time. While current therapeutic strategies target the causative pathway, they are ‘blind’ to the pathogenic cell involved. By combining clinicians, scientists, tissue imaging  and machine learning experts in our consortium we hope to solve the cell-number problem i.e. how many individual cell types make up a human joint”, says Chris Buckley.

Stephen, who leads the Computational and Single Cell Genomics Group at the Institute, adds: “by providing an essential reference map of the key components of healthy joints, this work will greatly help to accelerate our ongoing investigations of the cellular causes of arthritis”.

To deliver this ambitious programme of research, Chris, Mark and Steve will lead a multidisciplinary team spanning Oxford, Birmingham and Leeds, bringing together expertise in single cell analysis and imaging, with researchers who are specialists in the cell biology of joint tissues. 

The team have developed minimally invasive methods for extracting tissues from human joints, and through application of powerful genomic and imaging approaches, they can define and locate all types of cells present in key anatomical joint structures.

The researchers hope this approach may eventually lead to the identification of new therapeutic targets. Mark explains: “Building a 3D virtual map of cells and gene expression at single cell resolution will provide a technological leap forward and provide the basis to apply computer modelling to therapeutic design and development for joint disease, a major ambition for the Kennedy Institute.” 

The award is part of a £6.7M investment from the MRC to support 13 research projects across the UK that contribute to the Human Cell Atlas – a global initiative that aims to define and describe all cell types in the human body. 

Data generated through the Human Cell Atlas will be made accessible to researchers across the world through partnership with organisations including the European Bioinformatics Institute (EMBL-EBI). 

The Kennedy Institute also contributes to the Human Cell Atlas as part of a Wellcome Trust-funded study to map cellular activity in key tissues during the development of inflammatory disease.

Similar stories

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.